Clinical Trial Update: Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)

View source ↗

Summary

The document reports that the denileukin diftitox access program for patients currently receiving Ontak is no longer available. It signals a withdrawal of this …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma

Drugs mentioned

• ONTAK (denileukin diftitox)

Snippet

Sponsor: Eisai Inc. | Conditions: Cancer | Status: NO_LONGER_AVAILABLE